Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
100%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Active, not recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

active_not_recruiting120%
unknown120%
terminated120%
completed240%

Recent Activity

1 active trials
Showing 5 of 5
completedphase_2

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

NCT05054725
active_not_recruitingphase_1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
terminatedphase_1

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

NCT04916236
completedphase_1

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
unknownphase_1

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

NCT03634982

Clinical Trials (5)

Showing 5 of 5 trials
NCT05054725Phase 2

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Completed
NCT04185883Phase 1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active Not Recruiting
NCT04916236Phase 1

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Terminated
NCT03989115Phase 1

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Completed
NCT03634982Phase 1

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5